KURA ONCOLOGY, INC. Repayments of Long-Term Debt
KURA ONCOLOGY, INC. (KURA) reported Repayments of Long-Term Debt of $7.25 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2024-02-27
- KURA ONCOLOGY, INC. repayments of long-term debt for the quarter ending 2021-12-31 was $0.00.
- KURA ONCOLOGY, INC. repayments of long-term debt for the quarter ending 2021-09-30 was $0.00.
- KURA ONCOLOGY, INC. repayments of long-term debt for the quarter ending 2021-06-30 was $6.50M.
- KURA ONCOLOGY, INC. repayments of long-term debt for the quarter ending 2021-03-31 was $750.00K.
- KURA ONCOLOGY, INC. repayments of long-term debt for fiscal 2021 was $7.25M, a 2800.00% increase from fiscal 2020.
- KURA ONCOLOGY, INC. repayments of long-term debt for fiscal 2020 was $250.00K.
- KURA ONCOLOGY, INC. repayments of long-term debt for fiscal 2018 was $1.25M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $6.50M derived: sum of 3 quarters · filed 2024-02-27 | $7.25M 10-K · filed 2024-02-27 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $6.50M derived: sum of 2 quarters · filed 2022-11-03 | $7.25M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $6.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $7.25M 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $750.00K 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $250.00K 10-K · filed 2023-02-23 | |||
| 2018-12-31 | $250.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.00M derived: sum of 2 quarters · filed 2021-02-24 | $1.25M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $750.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $1.00M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $250.00K 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |